(202) 599-8435

FDA Fast Tracks Braeburn’s Long-Acting Buprenorphine Injection for Opioid Dependence

braeburnThe U.S. Food and Drug Administration (FDA) granted fast track designation for Braeburn Pharmaceuticals’ buprenorphine subcutaneous injection product to treat opioid use disorders. The medication’s manufacturer hopes to improve patient outcomes by offering pill-free options that administer treatment through novel delivery systems. Medications, such as buprenorphine, can be essential to improving patient outcomes and facilitating recovery. Read more here.

Print Friendly, PDF & Email
About the Author